- Home
- SNWV vs VNDA Comparison
SNWV vs VNDA Comparison
Compare SNWV & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNWV
- VNDA
- Stock Information
- Founded
- SNWV 2004
- VNDA 2002
- Country
- SNWV United States
- VNDA United States
- Employees
- SNWV N/A
- VNDA N/A
- Industry
- SNWV
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- SNWV
- VNDA Health Care
- Exchange
- SNWV NYSE
- VNDA Nasdaq
- Market Cap
- SNWV 234.2M
- VNDA 237.9M
- IPO Year
- SNWV N/A
- VNDA 2006
- Fundamental
- Price
- SNWV $26.20
- VNDA $4.34
- Analyst Decision
- SNWV
- VNDA Strong Buy
- Analyst Count
- SNWV 0
- VNDA 3
- Target Price
- SNWV N/A
- VNDA $15.33
- AVG Volume (30 Days)
- SNWV 46.1K
- VNDA 519.0K
- Earning Date
- SNWV 05-08-2025
- VNDA 05-07-2025
- Dividend Yield
- SNWV N/A
- VNDA N/A
- EPS Growth
- SNWV N/A
- VNDA N/A
- EPS
- SNWV N/A
- VNDA N/A
- Revenue
- SNWV $36,190,000.00
- VNDA $201,351,000.00
- Revenue This Year
- SNWV N/A
- VNDA $16.86
- Revenue Next Year
- SNWV N/A
- VNDA $39.78
- P/E Ratio
- SNWV N/A
- VNDA N/A
- Revenue Growth
- SNWV 61.50
- VNDA 13.37
- 52 Week Low
- SNWV $5.18
- VNDA $3.81
- 52 Week High
- SNWV $39.50
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- SNWV N/A
- VNDA 51.79
- Support Level
- SNWV N/A
- VNDA $4.17
- Resistance Level
- SNWV N/A
- VNDA $4.41
- Average True Range (ATR)
- SNWV 0.00
- VNDA 0.16
- MACD
- SNWV 0.00
- VNDA 0.03
- Stochastic Oscillator
- SNWV 0.00
- VNDA 73.61
About SNWV SANUWAVE HEALTH INC
SANUWAVE Health Inc is an ultrasound and shock wave technology company using patented systems of noninvasive, high-energy, acoustic shock waves or low-intensity and non-contact ultrasound for regenerative medicine and other applications. The company's focus is regenerative medicine utilizing noninvasive, acoustic shock waves or ultrasound to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's two primary systems are UltraMIST and PACE. UltraMIST and PACE are the only two Food and Drug Administration (FDA) approved directed energy systems for wound healing.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.